

At page 10, second paragraph, line 1, after "protein sequence," insert --SEQ ID NO: 28--.

At page 12, first paragraph, line 13, after "human VEGF," insert --SEQ ID NO: 33--.

At page 12, first paragraph, line 14, after "VEGF-D," insert --SEQ ID NO: 1--.

At page 12, first paragraph, line 15, after "VEGF-C," insert --SEQ ID NO: 29--.

At page 12, first paragraph, line 15, after "VEGF-B," insert --SEQ ID NO: 34--.

At page 12, first paragraph, line 16, after "PDGF-A," insert --SEQ ID NO: 30--.

At page 12, first paragraph, line 16, after "PDGF-B," insert --SEQ ID NO: 31--.

At page 12, first paragraph, line 17, after "PIGF2," insert --SEQ ID NO: 32--.

In the Drawings:

Applicants provide substitute Figs. 2 and 3 which have been amended to provide correct SEQ ID NO designations in conformity with the substitute sequence listing now provided.

At the end of the specification, kindly remove the sequence listing at pages 17 to 32 of the specification and the sequence listing submitted January 14, 1999, and attach the sequence listing provided herewith.

Applicant has amended the specification to provide a sequence listing for the polypeptides described in the drawings (Figures 2 and 3) as originally filed. In addition, Applicant has amended the specification to include appropriate sequence identifiers. Accordingly, Applicant provides a copy of the sequence listing in paper and electronic

format and a statement attesting to these facts.

No new matter is introduced by these amendments.


If there are any charges, or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date:

Oct. 22, 1997



Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045